ZNF79 inhibitors represent a class of compounds that interact with zinc finger protein 79 (ZNF79), a member of the C2H2-type zinc finger protein family. These proteins are characterized by the presence of zinc finger motifs, which are small, functional domains capable of binding to zinc ions, facilitating their interactions with DNA, RNA, or other proteins. ZNF79, like other zinc finger proteins, plays a key role in regulating gene expression through its ability to bind to specific DNA sequences. By modulating the activity of ZNF79, inhibitors can alter the transcriptional activity of genes under its control. This can impact cellular processes such as differentiation, proliferation, and signal transduction. ZNF79 inhibitors, therefore, affect the structural conformation or the DNA-binding ability of this protein, thereby disrupting the precise regulation of target genes involved in various cellular pathways.
The design of ZNF79 inhibitors is based on the understanding of the molecular structure of ZNF79, including its zinc-binding motifs and DNA-interaction regions. Researchers typically utilize high-throughput screening methods to identify small molecules that can bind specifically to the active site of ZNF79 or its allosteric sites, which can change its functional state. Advanced computational modeling and structural biology tools such as X-ray crystallography or NMR spectroscopy are often employed to investigate the inhibitor's binding characteristics and optimize their selectivity. Additionally, modifications to the chemical structure of these inhibitors are explored to enhance their binding affinity and stability within biological systems. This detailed understanding of ZNF79's structure and function allows for the development of inhibitors that can precisely modulate its role in gene expression, providing a valuable tool for studying the intricate mechanisms of transcriptional regulation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor that can affect protein synthesis, potentially altering the function of ZNF79. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor that can disrupt signaling, potentially influencing ZNF79's regulatory roles. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
MEK inhibitor that can affect the MAPK/ERK pathway, potentially modulating ZNF79 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 MAPK inhibitor that can alter stress response, potentially affecting ZNF79 function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor that can change stress response and apoptosis, potentially influencing ZNF79. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
MEK inhibitor that can disrupt MAPK/ERK signaling, potentially affecting ZNF79's activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor that can lead to protein accumulation, potentially impacting ZNF79 levels. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Proteasome inhibitor that can stabilize proteins, potentially affecting ZNF79's degradation. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
HDAC inhibitor that can change gene expression, potentially influencing ZNF79 activity. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
HDAC inhibitor that can alter chromatin structure, potentially modulating ZNF79 expression. | ||||||